Hepatocellular carcinoma(HCC), with its high incidence and mortality rate, is one of the most common malignant tumors. Despite recent development of a diagnostic and treatment method, the prognosis of HCC remains poor...Hepatocellular carcinoma(HCC), with its high incidence and mortality rate, is one of the most common malignant tumors. Despite recent development of a diagnostic and treatment method, the prognosis of HCC remains poor. Therefore, to provide optimal treatment for each patient with HCC, more precise and effective biomarkers are urgently needed which could facilitate a more detailed individualized decision-making during HCC treatment, including the following; risk assessment, early cancer detection, prediction of treatment or prognostic outcome. In the blood of cancer patients, accumulating evidence about circulating tumor cells and cell-free nucleic acids has suggested their potent clinical utilities as novel biomarker. This concept, so-called "liquid biopsy" is widely known as an alternative approach to cancer tissue biopsy. This method might facilitate a more sensitive diagnosis and better decision-making by obtaining genetic and epigenetic aberrations that are closely associated with cancer initiation and progression. In this article, we review recent developments based on the available literature on both circulating tumor cells and cell-free nucleic acids in cancer patients, especially focusing on Hepatocellular carcinoma.展开更多
Accumulating evidence has suggested the potential clinical utility of novel body fluid biomarkers,or“liquid biopsy”,using circulating tumor cells and cell-free nucleic acids from cancer patients.Noninvasive and repr...Accumulating evidence has suggested the potential clinical utility of novel body fluid biomarkers,or“liquid biopsy”,using circulating tumor cells and cell-free nucleic acids from cancer patients.Noninvasive and reproducible,liquid biopsy could provide the basis for individualized therapeutic strategies by identifying genetic and epigenetic aberrations that are closely associated with cancer initiation and progression.MicroRNAs(miRNAs)are short noncoding RNAs that post-transcriptionally regulate gene expression.They also play important roles in various physiological and developmental processes as oncogenic or tumor-suppressive regulators.Specific miRNA expression signatures have been identified in a number of human cancers.Circulating miRNAs have been detected in plasma and serum,and this in blood has attracted the attention of researchers for their potential as noninvasive biomarkers.Circulating miRNAs have emerged as tumor-associated biomarkers that reflect not only the existence of cancer,but also the dynamics,malignant potential,and drug resistance of tumors.Herein,we review the recent biological and clinical research on the circulating miRNAs of gastric cancer and discuss future perspectives for their clinical applications as a liquid biopsy.展开更多
文摘Hepatocellular carcinoma(HCC), with its high incidence and mortality rate, is one of the most common malignant tumors. Despite recent development of a diagnostic and treatment method, the prognosis of HCC remains poor. Therefore, to provide optimal treatment for each patient with HCC, more precise and effective biomarkers are urgently needed which could facilitate a more detailed individualized decision-making during HCC treatment, including the following; risk assessment, early cancer detection, prediction of treatment or prognostic outcome. In the blood of cancer patients, accumulating evidence about circulating tumor cells and cell-free nucleic acids has suggested their potent clinical utilities as novel biomarker. This concept, so-called "liquid biopsy" is widely known as an alternative approach to cancer tissue biopsy. This method might facilitate a more sensitive diagnosis and better decision-making by obtaining genetic and epigenetic aberrations that are closely associated with cancer initiation and progression. In this article, we review recent developments based on the available literature on both circulating tumor cells and cell-free nucleic acids in cancer patients, especially focusing on Hepatocellular carcinoma.
文摘Accumulating evidence has suggested the potential clinical utility of novel body fluid biomarkers,or“liquid biopsy”,using circulating tumor cells and cell-free nucleic acids from cancer patients.Noninvasive and reproducible,liquid biopsy could provide the basis for individualized therapeutic strategies by identifying genetic and epigenetic aberrations that are closely associated with cancer initiation and progression.MicroRNAs(miRNAs)are short noncoding RNAs that post-transcriptionally regulate gene expression.They also play important roles in various physiological and developmental processes as oncogenic or tumor-suppressive regulators.Specific miRNA expression signatures have been identified in a number of human cancers.Circulating miRNAs have been detected in plasma and serum,and this in blood has attracted the attention of researchers for their potential as noninvasive biomarkers.Circulating miRNAs have emerged as tumor-associated biomarkers that reflect not only the existence of cancer,but also the dynamics,malignant potential,and drug resistance of tumors.Herein,we review the recent biological and clinical research on the circulating miRNAs of gastric cancer and discuss future perspectives for their clinical applications as a liquid biopsy.
